A short term study of the additive effect of timolol and brimonidine on intraocular pressure

Eye

Volumn 16, Issue 1, 2002, Pages 39-43

  Arici, M K ^a   Sayici, M ^a   Toker, M I ^a   Erdogan H ^a   Topalkara, A ^a  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Brimonidine; Glaucoma; Timolol

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; ARTIFICIAL TEAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; CUSIMOLOL; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PLACEBO; POLYVINYL ALCOHOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEART RATE; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PROSPECTIVE STUDY; PUPIL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0036199610     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700035     Document Type: Article

References (19)

1. UK - 14,304, a potent and selective α-agonist for the characterization of α-adrenoceptor subtypes
2. Effects of brimonidine on aqueous humour dynamics in human eye
3. Brimonidine tartrate: A one month dose response study
4. The safety and efficacy of brimonidine tartrate 0.08%, 0.2%, 0.35% and 0.5% in normotensive subjects
5. A comparison of the safety and efficacy of twice-daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
6. A 1-year study of brimonidine twice daly in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial
7. The cardiovascular, pulmonary and ocular hypotensive effects of 0.2% brimonidine
8. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
9. Ongoing clinical assessment of the safety and efficacy of brimonidine compared with timolol: Year-three results
10. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
11. A fluorophotometric study of the effect of topical timolol on aqueous humour dynamics
12. The mechanism of timolol in lowering intraocular pressure in the normal eye
13. Brimonidine 0.2% behaviour on intraocular pressure in timolol-uncontrolled glaucomatous patients
14. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma
15. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure
16. Comparison of efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension
17. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma
18. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol